



Thomas Jefferson University  
Jefferson Digital Commons

---

Phase 1

Class of 2023

---

2-2021

## Likelihood of Germline Mutation with Solitary Unilateral Retinoblastoma Based on Patient Age at Presentation. A Real-World Analysis of 482 Consecutive Patients.

Martin Calotti

Carol L. Shields, MD


Philip Dockery, MD, MPH

Megan Ruben

Antonio Yaghy, MD

*See next page for additional authors*

Follow this and additional works at: [https://jdc.jefferson.edu/si\\_ctr\\_2023\\_phase1](https://jdc.jefferson.edu/si_ctr_2023_phase1)

 Part of the [Ophthalmology Commons](#), and the [Translational Medical Research Commons](#)

[Let us know how access to this document benefits you](#)

---

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).

---

**Authors**

Martin Calotti; Carol L. Shields, MD; Philip Dockery, MD, MPH; Megan Ruben; Antonio Yaghy, MD; Madalyne A. Sunday; Emily R. Duffner; Hannah J. Levin; Olivia S. Taylor; Sara E. Lally, MD; and Jerry A. Shields, MD

---

# Likelihood of Germline Mutation with Solitary Unilateral Retinoblastoma Based on Patient Age at Presentation. A Real-World Analysis of 482 Consecutive Patients


Martin Calotti, B.M.Sc., M.M.A.Sc., Carol L. Shields, M.D., Philip Dockery, M.D., M.P.H.,  
Megan Ruben, B.A., Antonio Yaghy\*, M.D., Madalyne A. Sunday, B.S., Emily R.  
Duffner\*\* B.S., Hannah J. Levin, B.S., Olivia S. Taylor, B.S., Sara E. Lally, M.D., Jerry A.  
Shields, M.D.

(\*) indicates primary project advisor

(\*\*) indicates another student who is declaring the same project as primary for SI

- Retinoblastoma (Rb) is an ocular tumor common in children





- Bilateral presentation  $\pm$  multifocal  $\rightarrow$  Germline mutation
- Unilateral presentation  $\rightarrow$  somatic mutation (?)
- Inheritance pattern is important for patient management
  - Germline  $\rightarrow$  More conservative treatment (i.e. chemotherapy)
  - Somatic  $\rightarrow$  Enucleation is common
- Previous studies: 7%-33% of solitary unilateral retinoblastomas are germline<sup>1-7</sup>
  - Problems: small sample size, patients were not followed long-term, and inclusion criteria only included genetic testing

# Objectives & Hypothesis

- Research Question
  - In children with unilateral retinoblastoma, what is the likelihood of germline mutation and does this likelihood vary based on age at initial presentation?
- Hypothesis
  - In children with unilateral retinoblastoma, there is a greater likelihood of germline mutation and this likelihood is greater in younger patients

# Approach & Results

- Study design: Retrospective chart review
- Data collection: Paper charts, excel, SAS Software Suite
- PICO:
  - 482 consecutive patients with solitary unilateral Retinoblastoma at Wills Eye Hospital between 1972 and 2020
  - Assessed the likelihood of germline inheritance based on age of presentation ( $\leq 1$  year vs.  $> 1$  year old)
- Inclusion criteria: unilateral Rb &  $> 1$  month follow-up



# Approach & Results

- Germline inheritance deemed “likely” if:
  1. Family History
  2. Germline Positive test
  3. Multifocal/extraocular tumor development

Family History

Genetic Testing

Bilateral Progression,  
Multifocal/extraocular  
tumor development

# Approach & Results

- Analysis
  - Likelihood ratio Chi-square test
  - ANOVA and Odds Ratios for differences between age groups
- Findings
  - 465 of 482 patients had sufficient follow-up time
  - 16% (n=72) of all unilateral Rb patients were likely to have germline disease (p<0.001)
  - 29% of patients ≤1 year old demonstrated a greater likelihood of germline inheritance (p=0.001)
  - Compared to patients >1 year of age (n=339), patients ≤1 year of age (n=126) demonstrated a greater likelihood of germline inheritance (p=0.001, OR=2.96 [1.55-5.65])

Outcomes	Age 0-12 months (n= 132) [n (%)]	Age >12-24 months (n= 122) [n (%)]	Age >24-36 months (n= 97) [n (%)]	Age >36 months (n= 131) [n (%)]	p-value	Total (N= 482) [N (%)]
Follow-up*	n=126	n=119	n=93	n=127		n=465
Duration (months) Mean (median, range)	99.1 (64.9, 0.1-465.1)	86.7 (42.8, 0.1-495.2)	75.6 (52.3, 0.1-357.6)	60.0 (40.4, 0.1-472.9)	<b>0.010</b>	81.4 (50.0, 0.1-495.2)
Patients without follow-up visits	6 (5)	3 (2)	4 (4)	4 (3)	--	17 (4)
Family history of retinoblastoma						
Negative	119 (90)	118 (98)	96 (99)	128 (98)	<b>0.004</b>	461 (96)
Positive	13 (10)	3 (2)	1 (1)	3 (2)		20 (4)
Genetic status	n=95	n=89	n=66	n=83		n=333
Somatic	65 (68)	72 (81)	62 (94)	77 (93)	<b>&lt;0.001</b>	276 (83)
Germline	30 (32)	17 (19)	4 (6)	6 (7)		57 (17)
Development of bilateral disease†	n=125	n=112	n=91	n=119		n=447
No	112 (90)	112 (100)	91 (100)	118 (99)	<b>0.035</b>	433 (97)
Yes	13 (10)	0 (0)	0 (0)	1 (1)		14 (3)
Development of new tumors‡	n=125	n=112	n=91	n=119		n=447
No	109 (87)	112 (100)	89 (98)	116 (97)	0.214	426 (95)
Yes	16 (13)	0 (0)	2 (2)	3 (3)		21 (5)
Likely germline disease‡	n=126	n=117	n=93	n=126		n=462
No	89 (71)	100 (85)	86 (92)	115 (91)	<b>0.001</b>	390 (84)
Yes	37 (29)	17 (17)	7 (8)	11 (9)		72 (16)
High risk features at enucleation	n=50	n=72	n=65	n=75		n=262
Enucleation	44 (88)	60 (83)	47 (72)	60 (80)	0.159	211 (81)
Enucleation with adjuvant IVC	6 (12)	12 (17)	18 (28)	15 (20)		51 (19)
Metastasis†	n=125	n=113	n=91	n=121		n=450
No	125 (100)	111 (98)	91 (100)	119 (98)	0.364	446 (99)
Yes	0 (0)	2 (2)	0 (0)	2 (2)		4 (1)
Systemic location of metastasis						
Bone	0 (0)	2 (100)	0 (0)	1 (50)	---	3 (75)
Brain	0 (0)	0 (0)	0 (0)	1 (50)		1 (25)
Death†	n=125	n=112	n=91	n=121		n=449
Total number of patients	0 (0)	0 (0)	0 (0)	2 (2)	---	2 (<1)

# Approach & Results

Outcomes	Age 0-3 months (n= 23) [n (%)]	Age >3-6 months (n= 27) [n (%)]	Age >6-9 months (n= 42) [n (%)]	Age >9-12 months (n= 40) [n (%)]	p-value	Total (N= 132) [N (%)]
Follow-up*	n=23	n=26	n=40	n=37		n=126
Duration (months) Mean (median, range)	98.1 (66.3, 1.2-410.0)	94.5 (81.5, 0.1-376.9)	101.0 (58.7, 1.9-465.1)	101.0 (63.3, 1.9-408.1)	0.989	99.1 (64.9, 0.1-465.1)
Patients without follow-up visits	0 (0)	1 (4)	2 (5)	3 (8)	--	6 (5)
Family history of retinoblastoma						
Negative	15 (65)	27 (100)	38 (90)	39 (98)	<b>&lt;0.001</b>	119 (90)
Positive	8 (35)	0 (0)	4 (10)	1 (3)		13 (10)
Genetic status	n=16	n=18	n=33	n=28		n=95
Somatic	5 (31)	14 (78)	24 (73)	22 (79)	<b>0.047</b>	65 (68)
Germline	11 (69)	4 (22)	9 (27)	6 (21)		30 (32)
Development of bilateral disease†	n=23	n=25	n=40	n=37		n=125
No	16 (70)	20 (80)	39 (98)	37 (100)	<b>0.001</b>	112 (90)
Yes	7 (30)	5 (20)	1 (3)	0 (0)		13 (10)
Development of new tumors‡	n=23	n=25	n=40	n=37		n=125
No	15 (65)	20 (80)	38 (95)	36 (97)	<b>0.004</b>	109 (87)
Yes	8 (35)	5 (20)	2 (5)	1 (3)		16 (13)
Likely germline disease‡	n=23	n=25	n=40	n=37		n=126
No	9 (39)	20 (80)	31 (76)	29 (78)	<b>0.009</b>	89 (71)
Yes	14 (61)	5 (20)	10 (24)	8 (22)		37 (29)
High risk features at enucleation	n=7	n=16	n=15	n=12		n=50
Enucleation	7 (100)	15 (94)	13 (87)	9 (75)	0.087	44 (88)
Enucleation with adjuvant IVC	0 (0)	1 (6)	2 (13)	3 (25)		6 (12)
Metastasis†	n=23	n=25	n=40	n=37		n=125
No	23 (100)	25 (100)	40 (100)	37 (100)	---	125 (100)
Yes	0 (0)	0 (0)	0 (0)	0 (0)		0 (0)
Systemic location of metastasis						
Bone	0 (0)	0 (0)	0 (0)	0 (0)	---	0 (0)
Brain	0 (0)	0 (0)	0 (0)	0 (0)		0 (0)
Death†	n=23	n=25	n=40	n=37		n=125
Total number of patients	0 (0)	0 (0)	0 (0)	0 (0)	---	0 (0)

# Approach & Results

Outcomes	OR (95% CI)	p-value
Family history of retinoblastoma		
All Patients ( $\leq 1$ year vs. $> 1$ year)	2.33 (0.70-7.81)	0.171
Infants * ( $\leq 3$ months vs. $> 3-12$ months)	<b>5.10 (1.09-23.81)</b>	<b>0.038</b>
Genetic status Rb1 germline mutation		
All Patients ( $\leq 1$ year vs. $> 1$ year)	<b>2.91 (1.56 – 5.44)</b>	<b>0.001</b>
Infants ( $\leq 3$ months vs. $> 3-12$ months)	<b>7.60 (1.87 – 30.86)</b>	<b>0.005</b>
Development of bilateral disease†		
All Patients ( $\leq 1$ year vs. $> 1$ year)	<b>17.28 (2.07 – 144.26)</b>	<b>0.009</b>
Infants ( $\leq 6$ months vs. $> 6-12$ months)	<b>23.94 (2.35 – 244.33)</b>	<b>0.007</b>
Development of new tumors†		
All Patients ( $\leq 1$ year vs. $> 1$ year)	<b>6.89 (2.38 – 19.98)</b>	<b>&lt;0.001</b>
Infants ( $\leq 6$ months vs. $> 6-12$ months)	<b>10.17 (2.28 – 45.30)</b>	<b>0.002</b>
Likely germline disease‡		
All Patients ( $\leq 1$ year vs. $> 1$ year)	<b>2.96 (1.55 – 5.65)</b>	<b>0.001</b>
Infants ( $\leq 3$ months vs. $> 3-12$ months)	<b>5.52 (1.93 – 15.83)</b>	<b>0.002</b>

# Conclusions

- Bilateral Rb is typically germline; inheritance of unilateral Rb is poorly understood
- Previous studies had small sample sizes and did not account for family history and development of bilateral tumors in the assessment of the real-world likelihood of unilateral Rb
- We found that 16% of 465 children with unilateral Rb likely have germline inheritance with a greater likelihood in children  $\leq 1$  year of age
- Implications: clinical management of germline Rb is treated more conservatively to preserve vision due to the greater likelihood of bilateral progression

# Future Directions

- What are the next steps for research and/or implementation?
- Implementing clinical assessments of unilateral Rb earlier may prove beneficial
  - Earlier detection of disease
  - Can influence management (targeted IAC vs enucleation) and preserve eyesight
- Our likelihood criteria can be incorporated into routine clinical assessment as opposed to just genetic testing

# Acknowledgements

- Carol L Shields
- Philip Dockery
- Megan Ruben
- Antonio Yaghy
- Madalyne Sunday
- Emily Duffner
- Hannah Levin
- Olivia Taylor
- Sara Lally
- Jerry Shields



1. Nichols KE, Walther S, Chao E, et al. Recent advances in retinoblastoma genetic research. *Curr Opin Ophthalmol.* 2009;20(5):351-5.
2. Berry JL, Lewis L, Zolfaghari E, et al. Lack of correlation between age at diagnosis and RB1 mutations for unilateral retinoblastoma: the importance of genetic testing. *Ophthalmic Genet.* 2018;(3)39:407-9.
3. Schüler A, Weber S, Neuhäuser M, et al. Age at diagnosis of isolated unilateral retinoblastoma does not distinguish patients with and without a constitutional RB1 gene mutation but is influenced by a parent-of-origin effect. *Eur J Cancer.* 2005;41(5):735-40.
4. Brichard B, Heusterspreute M, De Potter P, et al. Unilateral retinoblastoma, lack of familial history and older age does not exclude germline RB1 gene mutation. *Eur J Cancer.* 2006;42(1):65-72.
5. Gregersen PA, Urbak SF, Funding M, et al. Danish retinoblastoma patients 1943-2013 - genetic testing and clinical implications. *Acta Oncol.* 2016;55(4):412-7.
6. Yousef YA, Tbakhi A, Al-Hussaini M, et al. Mutational analysis of the RB1 gene and the inheritance patterns of retinoblastoma in Jordan. *Fam Cancer.* 2018;17(2):261-8.
7. Rojanaporn D, Boontawon T, Chareonsirisuthigul T, et al. Spectrum of germline RB1 mutations and clinical manifestations in retinoblastoma patients from Thailand. *Mol Vis.* 2018;24:778-88.